X

Drug Profile

Frakefamide

Alternative Names: BCH 3963; LEF; LEF 576; SPD 759

Latest Information Update: 25 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shire Pharmaceuticals Group
Class Analgesics
Mechanism of Action Opioid mu receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Pain

Most Recent Events

08 Jan 2019 Shire has been acquired and merged into Takeda
20 Sep 2001 AstraZeneca discontinued development of frakefamide with rights transferred back to Shire Pharmaceuticals
31 Jul 2001 AstraZeneca offers the rights for frakefamide back to Shire Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com